Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499867 | 0.84 | DPP4 (0.41) | DPP4TP53KDM4EMAPTTHRB | |
| SCHEMBL499521 | 0.84 | NOS3 (0.33) | — | |
| SCHEMBL500030 | 0.78 | USP30 (0.46) | KDM4EMAPTTHRBCTSDCTSE | |
| SCHEMBL499854 | 0.77 | NOS3 (0.39) | DPP4TP53MAPTGPR119BACE1 | |
| SCHEMBL499984 | 0.77 | MAPT (0.50) | TP53KDM4EMAPTTHRBGPR119 | |
| SCHEMBL1804057 | 0.74 | TP53 (0.46) | DPP4TP53KDM4EMAPTTHRB | |
| SCHEMBL1578454 | 0.73 | FPR2 (0.44) | TP53KDM4EMAPTTHRBGPR119 | |
| SCHEMBL21999659 | 0.73 | MAPT (0.53) | DPP4KDM4EMAPTTHRBGPR119 | |
| SCHEMBL499529 | 0.72 | USP30 (0.49) | TP53KDM4EGPR119USP30 | |
| SCHEMBL29196966 | 0.72 | MAPT (0.54) | DPP4KDM4EMAPTTHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-8618286-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-12-31 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| WO-2010000073-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | DPP4 616/4885TP53 4523/4885KDM4E 2340/4885 |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | DPP4 616/4885TP53 4523/4885KDM4E 2340/4885 |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | DPP4 616/4885TP53 4523/4885KDM4E 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.